Stockscreener 앱 받기
0.4947
2.57%
-0.0181
Femasys Inc 주식(FEMY)의 최신 뉴스
Femasys (NASDAQ: FEMY) director discloses notes, warrants and share stake - Stock Titan
Femasys Inc. Enters Omnibus Amendment and Issues Series D-1 Warrants – SEC 8-K Filing March 2026 - Minichart
Femasys amends warrants and notes, appoints new director to board - Investing.com
Femasys (NASDAQ: FEMY) director receives stock options for 35,200 shares - Stock Titan
Femasys Amends Financing Terms and Issues New Warrants - TipRanks
Femasys enters omnibus amendment and consent agreement on March 19, 2026SEC filing - marketscreener.com
Femasys Enters Omnibus Amendment And Consent Agreement On March 19, 2026SEC Filing - TradingView
Femasys Amends Notes and Warrants; Issues 16.38M New Warrants at $0.58 to Holders - TradingView
Femasys (FEMY) grants 16.4M Series D-1 warrants and appoints new independent director - Stock Titan
Femasys Inc. announced that it has received $12 million in funding - marketscreener.com
Femasys appoints anesthesiologist to board of directors By Investing.com - Investing.com South Africa
PharmaCyte Biotech (PMCB) logs neutral Form 4 as 10% FEMASYS (FEMY) owner - Stock Titan
Femasys (NASDAQ: FEMY) director Joshua Silverman files neutral Form 4 - Stock Titan
PharmaCyte Biotech (FEMY) reports 7.87% stake including warrants - Stock Titan
Femasys Inc. Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - marketscreener.com
Femasys appoints anesthesiologist to board of directors - Investing.com
Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors - Bitget
Femasys Inc. Appoints Kenneth D. Eichenbaum, M.D., M.S.E., to Board of Directors - Quiver Quantitative
Femasys appoints Dr. Kenneth D. Eichenbaum to board of directors - marketscreener.com
Femasys Appoints Dr. Kenneth D. Eichenbaum To Board Of Directors - TradingView
Femasys begins enrollment in pivotal trial for FemBloc device - Investing.com Nigeria
Jeremy Alexander Sipos Net Worth (2026) - GuruFocus
Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges - MSN
Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing - MSN
Femasys begins enrollment in pivotal trial for FemBloc device By Investing.com - Investing.com Australia
Non-surgical permanent birth control FemBloc begins final U.S. trial - Stock Titan
Femasys Inc. (NASDAQ:FEMY) Receives $5.50 Average Price Target from Analysts - Defense World
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits
Femasys (NASDAQ:FEMY) Now Covered by Analysts at Lake Street Capital - Defense World
Lake Street initiates Femasys stock coverage with buy rating By Investing.com - Investing.com Australia
Lake Street initiates Femasys stock coverage with buy rating - Investing.com
FEMY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FEMY Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FEMY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Femasys’s FemBloc Pivotal Trial Update: What Investors Should Watch in Women’s Health - TipRanks
Femasys Announces FemBloc® Permanent Birth Control Has - GlobeNewswire
New non-surgical permanent birth control clears key global quality hurdle - Stock Titan
Femasys Announces FemBloc Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access - Bitget
Sentiment Watch: Is Femasys Inc stock undervalued right nowJuly 2025 Setups & Low Risk Investment Opportunities - baoquankhu1.vn
Femasys receives CPT code approval for infertility treatment - Investing.com India
Femasys receives CPT code approval for infertility treatment By Investing.com - Investing.com Australia
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Trend Review: Can Femasys Inc benefit from deglobalization2025 Big Picture & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
AMA procedure code supports new infertility option for over 10M US women - Stock Titan
Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination - Bitget
Femasys (FEMY) CEO awarded 729,000 RSUs vesting through 2027 - Stock Titan
Femasys (NASDAQ: FEMY) CFO receives 342,000 restricted stock units - Stock Titan
Femasys (FEMY) CTO reports common stock and option holdings in Form 3 - Stock Titan
0.17%
0.75%
자본화:
|
볼륨(24시간):